Nitrous Oxide for Depression: What Patients Should Know

Nitrous Oxide Enters the TRD Conversation

A new Medscape analysis published in April 2026 takes a closer look at the growing body of research around nitrous oxide — commonly known as laughing gas — as a potential treatment for treatment-resistant depression (TRD). While nitrous oxide has long been used in dental and surgical settings for its anesthetic and anxiolytic properties, researchers are now investigating whether its rapid, short-lived antidepressant effects might offer a viable option for patients who haven't responded to conventional therapies.

The Medscape piece synthesizes several clinical studies, noting that nitrous oxide acts on NMDA (N-methyl-D-aspartate) receptors — the same receptor system targeted by ketamine. Early trials have shown that even brief inhalation sessions (often just one hour) can produce measurable antidepressant effects within hours, with some patients reporting mood improvements that persist for days or even weeks after a single session. However, researchers are careful to note that the evidence base remains limited, effect sizes vary considerably, and long-term durability data is still sparse.

How Does Nitrous Oxide Stack Up Against Ketamine?

For patients and providers already familiar with ketamine's trajectory in mental health care, the nitrous oxide conversation will feel both familiar and distinct. Both compounds work primarily through NMDA receptor antagonism, which is believed to trigger rapid glutamatergic signaling changes that can lift depressive symptoms far faster than traditional antidepressants. But the similarities largely end there.

Ketamine — particularly IV ketamine and the FDA-approved intranasal esketamine (Spravato) — has a significantly larger and more mature clinical evidence base. There are now hundreds of published trials and years of real-world data supporting ketamine's efficacy for TRD, suicidal ideation, and related conditions. Nitrous oxide, by contrast, is earlier in its research lifecycle. Most published studies involve small sample sizes, single-site designs, and short follow-up windows. The promising signal is real, but clinical translation remains limited.

There are also meaningful practical differences. Nitrous oxide requires specialized gas delivery equipment and controlled clinical environments. It cannot be self-administered and is not currently available through telehealth pathways. Ketamine, on the other hand, has an established — and growing — telehealth infrastructure. Oral ketamine (compounded lozenges or troches) can be prescribed and monitored remotely in many states, making it far more accessible for patients outside major metropolitan areas.

Side effect profiles also differ. Nitrous oxide sessions can produce nausea, dizziness, and dissociation, though the short duration of exposure typically limits intensity. Ketamine's dissociative effects are more pronounced and require active clinical monitoring, particularly in IV formulations. Both compounds carry abuse potential concerns, though ketamine's framework for supervised clinical use is considerably more developed.

What This Means for Patients Considering Ketamine Treatment

The growing interest in nitrous oxide actually reinforces a broader and important trend in psychiatry: the field is increasingly open to fast-acting, glutamate-targeting approaches for patients who have cycled through SSRIs, SNRIs, and other conventional antidepressants without relief. For TRD patients, this is genuinely meaningful. It signals that the treatment landscape is expanding — and that the scientific community is taking the need for rapid, effective interventions seriously.

That said, the practical implications for someone researching their options today are straightforward: ketamine is the proven, available option in this mechanistic class. Nitrous oxide, while scientifically interesting, is not yet a competitor in clinical availability. It lacks the regulatory framework, telehealth delivery infrastructure, and depth of safety data that ketamine has accumulated over the past decade.

If you are evaluating online ketamine providers, the nitrous oxide research is worth knowing about as context — it confirms that you are pursuing a treatment in a scientifically credible space. But it should not delay your decision or suggest you wait for an alternative that may be years from routine clinical use.

When vetting online ketamine providers, the fundamentals remain the same regardless of what's emerging in research: look for providers who conduct thorough intake screening (including psychiatric history, cardiac health, and substance use), offer structured follow-up care between sessions, and work with licensed prescribers who can adjust your protocol based on response. Reputable telehealth ketamine programs will also be transparent about what formulation they prescribe, typical session protocols, and how they handle safety concerns if they arise.

Out-of-pocket costs remain a live issue as well. Oral ketamine through telehealth typically runs $200–$500 per month depending on dosing and provider fees, while IV ketamine infusions can cost $400–$800 per session. Neither nitrous oxide nor ketamine is broadly covered by insurance for mental health indications, though esketamine (Spravato) has narrower insurance pathways for some TRD diagnoses. As the research field grows, coverage conversations may evolve — but patients should plan for self-pay costs in the near term.

You can read the original Medscape analysis here.